Article result template
I'm a little template short and blank. I link to void and keep hidden out.
2024-10-31T17:36:14+0000
I'm a little template short and blank. I link to void and keep hidden out.
2024-10-31T17:36:14+0000
ResMed shares surge to a one-year high following impressive 4Q earnings and a 10% dividend increase. With analysts rating the stock a "BUY", CEO Mick Farrell views the impact of weight loss drugs as a growth opportunity.
2024-08-07T01:33:30+0100
ResMed reports a significant revenue rise of 9% to $1.22 billion USD in the June quarter, highlighting its strong market position despite concerns over weight loss drugs impacting product demand.
2024-08-05T08:13:42+0100
Despite a modest 3% rise over the past year, analysts predict a stronger performance for Australia's healthcare sector in 2024, buoyed by population growth, technological innovations, and post-pandemic recovery.
2024-01-31T01:13:08+0000